|Arcturus Therapeutics Holdings Inc., of San Diego||ARCT-021||Self-replicating mRNA-based vaccine||COVID-19 prophylaxis||All 44 participants treated at the 2 higher doses had binding and/or neutralizing antibodies to SARS-CoV-2; peak geometric mean binding antibody titers were 4,959 for 5 µg single shot, 6,749 for 7.5 µg single shot, 16,642 for 5 µg prime-boosted and less than 400 for placebo; responder peak geometric mean neutralizing antibody titers were 32 for 5 µg single dose, 33 for 7.5 µg single dose and 46 for 5 µg prime-boost|
|Intra-Cellular Therapies Inc., of New York||ITI-LLAI||Long-acting injectable formulation of the antipsychotic lumateperone||Schizophrenia||Started the ITI-007-025 study testing the pharmacokinetics, safety and tolerability of single ascending doses of ITI-LLAI in patients with stable symptoms of schizophrenia|
|Intra-Cellular Therapies Inc., of New York||ITI-333||Antagonist of serotonin 5-HT2A receptors and a partial agonist at mu-opioid receptors||Healthy volunteers (eventually opioid use disorder)||Started the ITI-333-001 testing the safety, tolerability and pharmacokinetics of ascending doses of ITI-333|
|Nanology LLC, of Ft. Worth, Texas||SOR-007||Topical submicron particle formulation of the chemotherapy paclitaxel||Cutaneous metastases||Overall response rate was 27% for the 11 patients in 28-day treatment group and 54% for the 11 patients in the 56-day treatment group|
|Actinium Pharmaceuticals Inc., of New York||Iomab-B||I-131-labeled monoclonal antibody targeting CD45||Bone marrow transplant conditioning in active relapsed or refractory acute myeloid leukemia||Interim results from the Sierra study showed all of the 49 patients treated with Iomab-B successfully proceeded to bone marrow transplant (BMT) and achieved engraftment compared to 16% of the 56 patients who received physician's choice of salvage therapies; all 30 patients who crossed over from physician's choice to Iomab-B had successful engrafting after BMT|
|VBL Therapeutics Ltd., of Tel Aviv, Israel||Ofranergene obadenovec (VB-111)||CD95/TNF receptor modulator||Platinum-resistant ovarian cancer||Enrolled first patient in Europe into the ongoing Oval study; over 200 patients enrolled to date; next data safety monitoring committee review expected in the first quarter of 2021|
For more information about individual companies and/or products, see Cortellis.